Receptor Activity Modifying Protein 1 (RAMP1) is a single-pass membrane protein that is essential for forming functional calcitonin gene-related peptide (CGRP) receptors. RAMP1 belongs to a small family of receptor activity-modifying proteins that dictate ligand specificity and trafficking of the calcitonin receptor family[@poe2019][@russell2020].
The RAMP family consists of three members (RAMP1, RAMP2, and RAMP3) that each confer distinct pharmacology when co-expressed with either the calcitonin receptor (CALCR) or the calcitonin receptor-like receptor (CALCRL). RAMP1 specifically partners with CALCRL to create the canonical CGRP receptor (CALCRL/RAMP1), while CALCRL/RAMP2 forms the adrenomedullin receptor, and CALCRL/RAMP3 creates an alternate adrenomedullin receptor[@hay2020].
In the nervous system, CGRP signaling through RAMP1-containing receptors plays critical roles in:
This dual role—as both a driver of pathological migraine pain and a mediator of neuroprotective signaling—makes RAMP1 a complex therapeutic target with both risks and opportunities for drug development[@edvinsson2019][@bock2022].
The human RAMP1 gene is located on chromosome 2q36.1 and encodes a 175-amino acid protein. The gene consists of 4 exons spanning approximately 6 kb. The gene is expressed in various tissues, with highest levels in the trigeminal ganglion, dorsal root ganglia, and specific brain regions.
RAMP1 is a small type I membrane protein with a distinctive structure:
N-terminal Extracellular Domain (aa 1-100): This relatively long extracellular domain contains:
Transmembrane Domain (aa 100-120): Single alpha-helical transmembrane region that anchors RAMP1 in the plasma membrane and positions the extracellular and intracellular domains correctly.
Intracellular C-terminal Tail (aa 120-175): Short cytoplasmic tail containing:
The extracellular domain forms a rigid structure that orients the ligand-binding interface away from the membrane, while the transmembrane domain positions RAMP1 to interact with CALCRL in the correct orientation.
RAMP1 undergoes several post-translational modifications:
RAMP1's primary function is to enable CGRP receptor formation:
Receptor Assembly: RAMP1 forms a heterodimeric complex with CALCRL. This complex is essential for:
Ligand Specificity: The RAMP1 extracellular domain directly determines ligand specificity:
Species Differences: Human and rodent CGRP receptors show some pharmacological differences due to RAMP1 sequence variations, which is relevant for drug development.
RAMP1 is central to migraine pathophysiology:
Trigeminal System: RAMP1 is highly expressed in trigeminal ganglion neurons that innervate meningeal blood vessels. Activation of CGRP receptors on these neurons triggers the migraine pain pathway.
Vasodilation: CGRP is the most potent vasodilator known. CGRP-induced vasodilation of meningeal and cerebral blood vessels is a key component of migraine pathophysiology.
Central Processing: RAMP1 is expressed in brain regions involved in pain processing, including the thalamus and trigeminal nucleus caudalis.
Sensitization: CGRP signaling through RAMP1 can cause peripheral and central sensitization, amplifying pain signals.
CGRP signaling through RAMP1 provides neuroprotective effects:
Ischemic Protection: CGRP is released during cerebral ischemia and provides protective effects through RAMP1:
Axonal Protection: CGRP promotes survival of sensory neurons and may protect against axonal degeneration.
Anti-inflammatory Effects: CGRP can modulate immune cell function, reducing neuroinflammation that contributes to neurodegeneration[@meng2019].
While not the focus of this page, RAMP1-mediated CGRP signaling affects:
RAMP1 exhibits region-specific expression:
At the cellular level:
RAMP1 is directly implicated in migraine:
Expression: RAMP1 expression is elevated in trigeminal ganglion of migraine patients.
Genetic Studies: RAMP1 polymorphisms have been associated with migraine susceptibility in some populations.
Therapeutic Validation: The efficacy of CGRP receptor antagonists (gepants) and CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) confirms the importance of RAMP1-CGRP signaling in migraine.
CGRP-RAMP1 signaling contributes to migraine through:
Peripheral Activation: CGRP released from trigeminal nerve endings activates RAMP1-containing receptors on:
Central Sensitization: Prolonged CGRP signaling leads to sensitization of trigeminal nucleus caudalis neurons, lowering pain thresholds.
Cortical Spreading Depression: Some evidence links CGRP to cortical spreading depression, the purported correlate of migraine aura.
Paratriginal Nucleus Activation: RAMP1 in the paratriginal nucleus may contribute to migraine autonomic features.
RAMP1 is a major therapeutic target for migraine:
CGRP Receptor Antagonists (Gepants):
CGRP Receptor Antibodies:
Small Molecule RAMP1 Modulators:
CGRP-RAMP1 signaling has been studied in Alzheimer's disease:
Expression Changes: Some studies show altered CGRP and RAMP1 expression in AD brains.
Neuroprotection Potential: CGRP signaling through RAMP1 may protect against amyloid-beta toxicity.
Synaptic Function: CGRP modulates synaptic transmission; disrupted signaling may contribute to synaptic dysfunction.
Aβ Interaction: Some evidence suggests CGRP can reduce Aβ toxicity and may influence Aβ metabolism.
Neuroinflammation: CGRP has immunomodulatory effects that could influence neuroinflammation in AD.
Calcium Homeostasis: CGRP signaling affects calcium levels, relevant to calcium dysregulation in AD.
Potential Protection: The neuroprotective effects of CGRP may be beneficial in AD, though data are limited[@schurman2020].
RAMP1-mediated CGRP signaling is protective in stroke:
Endogenous Protection: CGRP is released during ischemia and provides neuroprotection.
Therapeutic Potential: Exogenous CGRP or CGRP analogs may reduce infarct size.
Vasodilation: Improved cerebral blood flow in ischemic penumbra.
Anti-apoptotic: Activation of pro-survival signaling pathways.
Anti-inflammatory: Modulation of post-ischemic inflammation.
Anti-oxidant: Reduction of oxidative stress[@yuan2019].
Limited evidence suggests CGRP-RAMP1 involvement in PD:
Expression Changes: Some studies show altered CGRP levels in PD patients.
Neuroprotection: CGRP may protect dopaminergic neurons.
Motor Function: CGRP may influence motor control circuits.
However, data are much more limited than for migraine or stroke[@chen2022].
| Partner | Interaction Type | Functional Role |
|---|---|---|
| CALCRL | Heterodimer formation | CGRP receptor complex |
| CALCR | Alternative receptor | Amylin receptor formation |
| CGRP (αCGRP, βCGRP) | Ligand binding | Receptor activation |
| Receptor activity-modifying proteins | Heterodimerization | Determines ligand specificity |
| β-arrestin | Signal transduction | G protein-independent signaling |
| GRK | Phosphorylation | Receptor desensitization |
CGRP-RAMP1 activates multiple signaling cascades:
cAMP/PKA Pathway: Primary pathway activated by CGRP, leading to:
MAPK Pathways: ERK1/2 and other MAPK pathways for:
PI3K/Akt Pathway: Mediates neuroprotective effects.
PLC/IP3 Pathway: Secondary signaling for:
Phenotype: Ramp1⁻/⁻ mice show:
Migraine Models: Reduced migraine-like behaviors in animal models.
Ramp1 overexpression: Enhances CGRP receptor function and sensitivity.
Migraine models: RAMP1 expression correlates with migraine-like behaviors.
Stroke models: CGRP-RAMP1 signaling is protective.
Study of RAMP1 employs various approaches:
Gepants (CGRP receptor antagonists):
CGRP/CGRP receptor antibodies:
RAMP1-specific modulators: Target RAMP1 rather than entire receptor.
Allosteric modulators: Bind at distinct sites to modulate receptor function.
Gene therapy: Approaches to modulate RAMP1 expression.